Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2006, Article ID 59089, 38 pages
http://dx.doi.org/10.1155/IDOG/2006/59089
Meeting Abstracts

Proceedings From the First Asia-Oceania Research Organisation on Genital Infections and Neoplasia (AOGIN) Meeting

Edited by Sebastian Faro

Department of Obstetrics and Gynecology, The Woman's Hospital of Texas, Houston Texas 77054, USA

Received 6 February 2006; Accepted 15 May 2006

Copyright © 2006 Sebastian Faro. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Descriptive Epidemiology Group of IARC. Globocan 2002.
  2. N Muñoz, F X Bosch, S De Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003. View at Google Scholar
  3. G M Clifford, J S Smith, T Aguado, and S Franceschi, “Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis,” British Journal of Cancer, vol. 89, no. 1, pp. 101–105, 2003. View at Publisher · View at Google Scholar
  4. F X Bosch, A Lorincz, N Muñoz, C JLM Meijer, and K V Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. View at Google Scholar
  5. N F Schlecht, R W Platt, E Duarte-Franco et al., “Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia,” Journal of the National Cancer Institute, vol. 95, no. 17, pp. 1336–1343, 2003. View at Google Scholar
  6. J J Carter, L A Koutsky, J P Hughes et al., “Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection,” Journal of Infectious Diseases, vol. 181, no. 6, pp. 1911–1919, 2000. View at Publisher · View at Google Scholar
  7. M Ferguson, A Heath, S Johnes, S Pagliusi, and J Dillner, “Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses,” International Journal of Cancer, vol. 118, no. 6, pp. 1508–1514, 2006. View at Publisher · View at Google Scholar
  8. T C Jr Wright, J T Cox, L S Massad, L B Twiggs, and E J Wilkinson, “2001 consensus guidelines for the management of women with cervical cytological abnormalities,” Journal of the American Medical Association, vol. 287, no. 16, pp. 2120–2129, 2002. View at Publisher · View at Google Scholar
  9. L A Koutsky, K A Ault, C M Wheeler et al., “A controlled trial of a human papillomavirus type 16 vaccine,” The New England Journal of Medicine, vol. 347, no. 21, pp. 1645–1651, 2002. View at Publisher · View at Google Scholar
  10. D M Harper, E L Franco, C M Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar
  11. M E Sherman, M Schiffman, and J T Cox, “Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS),” Journal of the National Cancer Institute, vol. 94, no. 2, pp. 102–107, 2002. View at Google Scholar
  12. J T Cox, M Schiffman, and D Solomon, “ASCUS-LSIL Triage Study (ALTS) Group. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy,” American Journal of Obstetrics and Gynecology, vol. 188, no. 6, pp. 1406–1412, 2003. View at Publisher · View at Google Scholar
  13. J Cuzick, A Szarewski, H Cubie et al., “Management of women who test positive for high-risk types of human papillomavirus: the HART study,” Lancet, vol. 362, no. 9399, pp. 1871–1876, 2003. View at Publisher · View at Google Scholar
  14. M Arbyn, F Buntinx, M van Ranst, E Paraskevaidis, P L Martin-Hirsch, and J Dillner, “Virologic versus cytologic triage of women with equivocal pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia,” Journal of the National Cancer Institute, vol. 96, no. 4, pp. 280–293, 2004. View at Google Scholar
  15. J Cuzick, C Clavel, U Petry et al., “Overview of the European and North American studies on HPV testing in primary cervical cancer sreening,” International Journal of Cancer, vol. 119, no. 5, pp. 1095–101, 2006. View at Publisher · View at Google Scholar
  16. J Cuzick, E Beverley, L Ho et al., “HPV testing in primary screening of older women,” British Journal of Cancer, vol. 81, no. 3, pp. 554–558, 1999. View at Publisher · View at Google Scholar
  17. C Clavel, M Masure, M Levert et al., “Human Papillomavirus detection by the Hybrid Capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions,” Diagnostic Molecular Pathology, vol. 9, no. 3, pp. 145–150, 2000. View at Publisher · View at Google Scholar
  18. K U Petry, S Menton, M Menton et al., “Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients,” British Journal of Cancer, vol. 88, no. 10, pp. 1570–1577, 2003. View at Publisher · View at Google Scholar
  19. H Hoyer, C Scheungraber, R Kuehne-Heid et al., “Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting,” International Journal of Cancer, vol. 116, no. 1, pp. 136–143, 2005. View at Publisher · View at Google Scholar
  20. A A Brink, G D Zielinski, R D Steenbergen, P J Snijders, and C JLM Meijer, “Clinical relevance of human papillomavirus testing in cytopathology,” Cytopathology, vol. 16, no. 1, pp. 7–12, 2005. View at Publisher · View at Google Scholar
  21. S Ratnam, E L Franco, and A Ferenczy, “Human papillomavirus testing for primary screening of cervical cancer precursors,” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 9, pp. 945–951, 2000. View at Google Scholar
  22. S L Kulasingam, J P Hughes, N B Kiviat et al., “Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral,” Journal of the American Medical Association, vol. 288, no. 14, pp. 1749–1757, 2002. View at Publisher · View at Google Scholar
  23. P L Martin-Hirsch, E Paraskevaidis, and H Kitchener, “Surgery for cervical intraepithelial neoplasia,” Cochrane Database of Systematic Reviews, no. 2, p. CD001318, 2000. View at Google Scholar
  24. M F Mitchell, G Tortolero-Luna, E Cook, L Whittaker, H Rhodes-Morris, and E Silva, “A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix,” Obstetrics and Gynecology, vol. 92, no. 5, pp. 737–744, 1998. View at Publisher · View at Google Scholar
  25. S Tangtrakul, V Linasmita, N Israngura, S Srisupundit, S Bullangpoti, and S Wilailak, “Detection of residual disease by cytology in patients with cervical intraepithelial neoplasia III post-large loop excision of the transformation zone,” Journal of Obstetrics and Gynaecology Research, vol. 28, no. 2, pp. 95–98, 2002. View at Publisher · View at Google Scholar
  26. N J Agnantis, A Sotiriadis, and E Paraskevaidis, “The current status of HPV DNA testing,” European Journal of Gynaecological Oncology, vol. 24, no. 5, pp. 351–356, 2003. View at Google Scholar
  27. G D Zielinski, A G Bais, T J Helmerhorst et al., “HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis,” Obstetrical & Gynecological Survey, vol. 59, no. 7, pp. 543–553, 2004. View at Google Scholar
  28. Singapore Health Facts 2004, Ministry of Health Singapore. http://www.moh.gov.sg/corp/publications/statistics/principal.do.
  29. A Seow, K W Puay, C K Seng et al., “Trends in cancer incidence in Singapore 1968-2002,” Singapore Cancer Registry. Accessible at Singapore Health Facts 2004, Ministry of Health Singapore. http://www.moh.gov.sg/corp/publications/statistics/principal.do.
  30. N Mubiayi, E Bogaert, F Boman et al., “Cytological history of 148 women presenting with invasive cervical cancer,” Gynecologie Obstetrique Fertilite, vol. 30, no. 3, pp. 210–217, 2002. View at Publisher · View at Google Scholar
  31. M Broadstock, “Effectiveness and cost effectiveness of automated and semi-automated cervical screening devices: a systematic review of the literature,” New Zealand Medical Journal, vol. 114, no. 1135, pp. 311–313, 2001. View at Google Scholar
  32. D D Davey, “Papanicolaou smear 5-year retrospective review: what is required by the Clinical Laboratory Improvement Amendments of 1988?” Archives of Pathology and Laboratory Medicine, vol. 121, no. 3, pp. 296–298, 1997. View at Google Scholar
  33. N N Nissen and P Martin, “Hepatocellular carcinoma: the high-risk patient,” Journal of Clinical Gastroenterology, vol. 35, no. 5 suppl 2, pp. S79–S85, 2002. View at Publisher · View at Google Scholar
  34. S L Kulasingam and E R Myers, “Potential health and economic impact of adding a human papillomavirus vaccine to screening programs,” Journal of the American Medical Association, vol. 290, no. 6, pp. 781–789, 2003. View at Publisher · View at Google Scholar
  35. G M Clifford, J S Smith, M Plummer, N Muñoz, and S Franceschi, “Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis,” British Journal of Cancer, vol. 88, no. 1, pp. 63–73, 2003. View at Publisher · View at Google Scholar
  36. E H Tay, “Pap smear screening for cervical cancer in Singapore: issues to consider,” Singapore Medical Journal, vol. 45, no. 6, pp. 244–246, 2004. View at Google Scholar
  37. S Hallez, P Simon, F Maudoux et al., “Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia,” Cancer Immunology Immunotherapy, vol. 53, no. 7, pp. 642–650, 2004. View at Publisher · View at Google Scholar
  38. C M Corona Gutierrez, A Tinoco, T Navarro et al., “Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus,” Human Gene Therapy, vol. 15, no. 5, pp. 421–431, 2004. View at Publisher · View at Google Scholar
  39. M van Ballegooijen, E van den Akker-van Marle, J Patnick et al., “Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness,” European Journal of Cancer, vol. 36, no. 17, pp. 2177–2188, 2000. View at Publisher · View at Google Scholar
  40. P Sasieni, J Adams, and J Cuzick, “Benefit of cervical screening at different ages: evidence from the UK audit of screening histories,” British Journal of Cancer, vol. 89, no. 1, pp. 88–93, 2003. View at Publisher · View at Google Scholar
  41. 2005 Philippine Cancer Facts and Estimates. The Philippine Cancer Society which publishes this data is developing a website, http://www.philcancer.org.
  42. F X Bosch, M M Manos, N Muñoz et al., “Prevalence of human papillomavirus in cervical cancer: a worldwide perspective,” Journal of the National Cancer Institute, vol. 87, no. 11, pp. 796–802, 1995, Limson G, Ngelangel C; Munoz H (Philippine contributors) to IARC-WHO-Int. Biological study group on Cervical Cancer. View at Publisher · View at Google Scholar
  43. V Shanta, S Krishnamurthi, C K Gajalakshmi, R Swaminathan, and K Ravichandran, “Epidemiology of cancer of the cervix: global and national perspective,” Journal of the Indian Medical Association, vol. 98, no. 2, pp. 49–52, 2000. View at Google Scholar
  44. L Denny, L Kuhn, L Risi et al., “Two-stage cervical cancer screening: an alternative for resource-poor settings,” American Journal of Obstetrics and Gynecology, vol. 183, no. 2, pp. 383–388, 2000. View at Publisher · View at Google Scholar
  45. WHO Report. State of the art research and development. http://www.who.int/vaccine_research/documents/dip%20814.pdf.
  46. R Chatterjee, B Mandal, and S Bandyopadhyay, “Detection of HPV DNA in cervical carcinomas by PCR and hybrid capture assay,” Indian Journal of Pathology and Microbiology, vol. 46, no. 4, pp. 596–599, 2003. View at Google Scholar
  47. S Franceschi, T Rajkumar, S Vaccarella et al., “Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study,” International Journal of Cancer, vol. 107, no. 1, pp. 127–133, 2003. View at Publisher · View at Google Scholar
  48. S Franceschi, R Rajkumar, P J Snijders et al., “Papillomavirus infection in rural women in southern India,” British Journal of Cancer, vol. 92, no. 3, pp. 601–606, 2005. View at Publisher · View at Google Scholar
  49. P S Basu, R Sankaranarayanan, R Mandal et al., “Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata,” International Journal of Gynecological Cancer, vol. 13, no. 5, pp. 626–632, 2003. View at Publisher · View at Google Scholar
  50. R Sankaranarayanan, R Rajkumar, S Arrossi et al., “Determinants of participation of women in a cervical cancer visual screening trial in rural south India,” Cancer Detection and Prevention, vol. 27, no. 6, pp. 457–465, 2003. View at Publisher · View at Google Scholar
  51. Bhatla et al. 2005. Unpublished data.
  52. B M Nene, S Deshpande, K Jayant et al., “Early detection of cervical cancer by visual inspection: a population-based study in rural India,” International Journal of Cancer, vol. 68, no. 6, pp. 770–773, 1996. View at Publisher · View at Google Scholar
  53. R Sankaranarayanan, S Thara, A Sharma et al., “Accuracy of conventional cytology: results from a multicentre screening study in India,” Journal of Medical Screening, vol. 11, no. 2, pp. 77–84, 2004. View at Publisher · View at Google Scholar
  54. R Sankaranarayanan, P Basu, R S Wesley et al., “Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa,” International Journal of Cancer, vol. 110, no. 6, pp. 907–913, 2004. View at Publisher · View at Google Scholar
  55. S S Shastri, K Dinshaw, G Amin et al., “Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India,” Bulletin of the World Health Organization, vol. 83, no. 3, pp. 186–194, 2005. View at Google Scholar
  56. C H Wen, “China's plans to curb cervical cancer,” Lancet Oncology, vol. 6, no. 3, pp. 139–141, 2005. View at Publisher · View at Google Scholar
  57. J Belinson, Y L Qiao, R Pretorius et al., “Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia,” Gynecologic Oncology, vol. 83, no. 2, pp. 439–344, 2001. View at Publisher · View at Google Scholar
  58. J L Belinson, Y L Qiao, R G Pretorius et al., “Shanxi province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology,” International Journal of Gynecological Cancer, vol. 13, no. 6, pp. 819–826, 2003. View at Publisher · View at Google Scholar
  59. D M Parkin, S L Whelena, J Ferlay et al., Cancer Incidence in Five Continents: Volume VII, IARC Scientific, Lyon, France, 1997.
  60. “Hong Kong College of Obstreticians and Gynaecologists (HKCOG). Guidelines on the management of an abnormal cervical smear,” HKCOG Guidelines No. 3. Hong Kong, China: HKCOG; Revised 2002. http://www.hkcog.obg.cuhk.edu.hk/docs/college_guidelines.
  61. Hong Kong College of Pathology. Basic Criteria for a Cervical Cytology Screening Laboratory.
  62. “Cervical Cytology Practice Guidelines,” Pub. Hong Kong Society of Cytology. 2002. http://www.cytology.org.hk/Download/Final%20Draft2.pdf.
  63. A N Cheung, E F Szeto, B S Leung, U S Khoo, and A W Ng, “Liquid based cytology and conventional cervical smears: a comparison study in an Asian screening population,” Cancer Cytopathology, vol. 99, no. 6, pp. 331–335, 2003. View at Google Scholar
  64. A N Cheung, E F Szeto, K M Ng et al., “Atypical squamous cells of undetermined significance on cervical smears: follow-up study of an Asian screening population,” Cancer, vol. 102, no. 2, pp. 74–80, 2004. View at Publisher · View at Google Scholar
  65. R T Emeny, C M Wheeler, K U Jansen et al., “Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine,” Journal of Virology, vol. 76, no. 15, pp. 7832–7842, 2002. View at Publisher · View at Google Scholar
  66. K Ault, A Guiliano, R Edwards et al., “Immunogenicity of human papilloma virus 18 virus particles: results of a phase I vaccine trial,” International Journal of STD and AIDS, vol. 12, pp. 195–196, 2001. View at Google Scholar
  67. D R Brown, J T Bryan, J M Schroeder et al., “Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer,” Journal of Infectious Diseases, vol. 184, no. 9, pp. 1183–1186, 2001. View at Publisher · View at Google Scholar
  68. “IARC Press Release following Cervix Cancer Screening Meeting,” April 2004. http://www.iarc.fr/ENG/Press_Releases/Evaluation.pdf.
  69. J Cuzick, P Sasieni, P Davies et al., “A systematic review of the role of human papillomavirus testing within a cervical screening programme,” Health Technology Assessment, vol. 3, no. 14, pp. i–iv, 1–196, 1999. View at Google Scholar
  70. L L Villa, R L Costa, C A Petta et al., “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial,” Lancet Oncology, vol. 6, no. 5, pp. 271–278, 2005. View at Publisher · View at Google Scholar
  71. Mao et al. 44th ICAAC: Abstract 3741. Presented November 2004 http://www.medscape.com/viewarticle/493010.
  72. N Muñoz, F X Bosch, X Castellsagué et al., “Against which human papillomavirus types shall we vaccinate and screen? The international perspective,” International Journal of Cancer, vol. 111, no. 2, pp. 278–285, 2004. View at Google Scholar
  73. F X Bosch, A Lorincz, N Muñoz, C JLM Meijer, and K V Shah, “The causal relation between human papillomavirus and cervical cancer,” Journal of Clinical Pathology, vol. 55, no. 4, pp. 244–265, 2002. View at Google Scholar
  74. D M Harper, E L Franco, C Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar
  75. L A Pinto, P E Castle, R B Roden et al., “HPV-16 VLP vaccine elicits a broadspectrum of cytokine responses in whole blood,” Vaccine, vol. 23, no. 27, pp. 3555–64, 2005. View at Publisher · View at Google Scholar
  76. L F Zhang, J Zhou, S Chen et al., “HPV6b virus like particles are potent immunogens without adjuvant in man,” Vaccine, vol. 18, no. 11-12, pp. 1051–1058, 2000. View at Publisher · View at Google Scholar
  77. S E Goldstone, J M Palefsky, M T Winnett, and J R Neefe, “Activity of HspE7, a novel immunotherapy, in patients with anogenital warts,” Diseases of the Colon and Rectum, vol. 45, no. 4, pp. 502–507, 2002. View at Publisher · View at Google Scholar
  78. B Klencke, M Matijevic, R G Urban et al., “Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101,” Clinical Cancer Research, vol. 8, no. 5, pp. 1028–1037, 2002. View at Google Scholar
  79. L K Borysiewicz, A Fiander, M Nimako et al., “A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,” Lancet, vol. 347, no. 9014, pp. 1523–1527, 1996. View at Publisher · View at Google Scholar
  80. T D De Gruijl, H J Bontkes, A JC Van den Muysenberg et al., “Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix,” European Journal of Cancer, vol. 35, no. 3, pp. 490–497, 1999. View at Publisher · View at Google Scholar
  81. I H Frazer, R W Tindle, G J Fernando et al., “Safety and immunogenicity of HPV16 E7/Algammulin immunotherapy for cervical cancer,” in Vaccines for Human Papillomavirus Infection and Anogenital Disease, R W Tindle, Ed., pp. 91–104, Landes Bioscience, Austin, Tex, 1999. View at Google Scholar
  82. A Ferrara, M Nonn, P Sehr et al., “Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients,” Journal of Cancer Research and Clinical Oncology, vol. 129, no. 9, pp. 521–530, 2003. View at Publisher · View at Google Scholar
  83. E J Davidson, C M Boswell, P Sehr et al., “Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins,” Cancer Research, vol. 63, no. 18, pp. 6032–6041, 2003. View at Google Scholar
  84. P J Baldwin, S H Van Der Burg, C M Boswell et al., “Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia,” Clinical Cancer Research, vol. 9, no. 14, pp. 5205–5213, 2003. View at Google Scholar
  85. L Muderspach, S Wilczynski, L Roman et al., “A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive,” Clinical Cancer Research, vol. 6, no. 9, pp. 3406–3416, 2000. View at Google Scholar
  86. L A Koutsky, K A Ault, C M Wheeler et al., “A controlled trial of a human papillomavirus type 16 vaccine,” New England Journal of Medicine, vol. 347, no. 21, pp. 1703–1705, 2002. View at Publisher · View at Google Scholar
  87. D M Harper, E L Franco, C Wheeler et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” Lancet, vol. 364, no. 9447, pp. 1757–1765, 2004. View at Publisher · View at Google Scholar · View at PubMed
  88. J E Ramirez, D M Ramos, L Clayton, S Kanowitz, and A-B Moscicki, “Genital human papillomavirus infections: knowledge, perception of risk, and actual risk in a nonclinic population of young women,” Journal of Women's Health, vol. 6, no. 1, pp. 113–121, 1997. View at Google Scholar
  89. H Baer, S Allen, and L Braun, “Knowledge of human papillomavirus infection among young adult men and women: implications for health education and research,” Journal of Community Health, vol. 25, no. 1, pp. 67–78, 2000. View at Publisher · View at Google Scholar
  90. M Pitts and T Clarke, “ Human papillomavirus infections and risks of cervical cancer: what do women know?” Health Education Research, vol. 17, no. 6, pp. 706–714, 2002. View at Publisher · View at Google Scholar
  91. R Anhang, T C Jr Wright, L Smock, and S J Goldie, “Women's desired information about human papillomavirus,” Cancer, vol. 100, no. 2, pp. 315–320, 2004. View at Publisher · View at Google Scholar
  92. K McCaffery, J Waller, S Forrest, L Cadman, A Szarewski, and J Wardle, “Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact,” BJOG: An International Journal of Obstetrics and Gynaecology, vol. 111, no. 12, pp. 1437–1443, 2004. View at Publisher · View at Google Scholar
  93. H S Holgate and C Longman, “Some peoples' psychological experiences of attending a sexual health clinic and having a sexually transmitted infection,” Journal of the Royal Society of Health, vol. 118, no. 2, pp. 94–96, 1998. View at Google Scholar
  94. M L Keller, V Von Sadovszky, B Pankratz, and J Hermsen, “Self-disclosure of HPV infection to sexual partners,” Western Journal of Nursing Research, vol. 22, no. 3, pp. 285–302, 2000. View at Publisher · View at Google Scholar
  95. M K Pitts, C Fox, J Willis, and J Anderson, “What do gay men know about human papillomavirus? Australian gay men's knowledge and experience of anal cancer screening and human papillomavirus,” Sexually Transmitted Diseases, 2006, Epub ahead of print. View at Google Scholar
  96. in IARC Handbooks of Cancer Prevention Volume 10: Cervix Cancer Screening, pp. 142–143, IARC Press, Lyon, France, 2005.
  97. S Sato, G Matsunaga, R Konno, and A Yajima, “Mass screening for cancer of the uterine cervix in Miyagi Prefecture, Japan: effects and problems,” Acta Cytologica, vol. 42, no. 2, pp. 299–304, 1998. View at Google Scholar
  98. R Konno, M Suzuki, M Ohwada et al., “Recommendation of expansion of screening for cervical cancer to women under 30 years of age,” Obstetrics and Gynecology, vol. 71, pp. 1907–1913, 2004 (Japanese). View at Google Scholar
  99. Behavioral Risk Factor Surveillance System (BRFSS). http://www.cdc.gov/brfss/.
  100. R Konno, K Nagai, S Netsu et al., “Uterine cancer screening,” Diagnosis and Treatment, vol. 93, pp. 1575–1582, 2005 (Japanese). View at Google Scholar
  101. L Denny, L Kuhn, A Pollack, H Wainwright, and T C Jr Wright, “Evaluation of alternative methods of cervical cancer screening for resource-poor settings,” Cancer, vol. 89, no. 4, pp. 826–833, 2000. View at Publisher · View at Google Scholar
  102. L Denny, L Kuhn, A Pollack, and T C Jr Wright, “Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance,” Cancer, vol. 94, no. 6, pp. 1699–1707, 2002. View at Publisher · View at Google Scholar · View at PubMed
  103. H S Cronjé, G P Parham, B F Cooreman, A de Beer, P Divall, and R H Bam, “A comparison of four screening methods for cervical neoplasia in a developing country,” American Journal of Obstetrics and Gynecology, vol. 188, no. 2, pp. 395–400, 2003. View at Publisher · View at Google Scholar
  104. L Gaffikin, P D Blumenthal, J McGrath, and Z M Chirenje, “Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project,” Lancet, vol. 353, no. 9156, pp. 869–873, 1999. View at Publisher · View at Google Scholar
  105. F Ghaemmaghami, N Behtash, M Modares Gilani, A Mousavi, M Marjani, and R Moghimi, “Visual inspection with acetic acid as a feasible screening test for cervical neoplasia in Iran,” International Journal of Gynecological Cancer, vol. 14, no. 3, pp. 465–469, 2004. View at Publisher · View at Google Scholar
  106. A El-Shalakany, S S Hassan, E Ammar, M A Ibrahim, M A Salam, and M Farid, “Direct visual inspection of the cervix for the detection of premalignant lesions,” Journal of Lower Genital Tract Disease, vol. 8, no. 1, pp. 16–20, 2004. View at Publisher · View at Google Scholar
  107. H de Vuyst, P Claeys, S Njiru et al., “Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography,” International Journal of Gynecology and Obstetrics, vol. 89, no. 2, pp. 120–126, 2005. View at Publisher · View at Google Scholar · View at PubMed
  108. A S Doh, N N Nkele, P Achu, F Essimbi, O Essame, and B Nkegoum, “Visual inspection with acetic acid and cytology as screening methods for cervical lesions in Cameroon,” International Journal of Gynecology and Obstetrics, vol. 89, no. 2, pp. 167–173, 2005. View at Publisher · View at Google Scholar · View at PubMed
  109. J Jeronimo, O Morales, J Horna et al., “Visual inspection with acetic acid for cervical cancer screening outside of low-resource settings,” Revista Panamericana de Salud Publica, vol. 17, no. 1, pp. 1–5, 2005. View at Google Scholar
  110. J L Belinson, R G Pretorius, W H Zhang, L Y Wu, Y L Qiao, and P Elson, “Cervical cancer screening by simple visual inspection after acetic acid,” Obstetrics and Gynecology, vol. 98, no. 3, pp. 441–444, 2001. View at Publisher · View at Google Scholar
  111. R Sankaranarayanan, P Basu, R S Wesley et al., “Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa,” International Journal of Cancer, vol. 110, no. 6, pp. 907–913, 2004. View at Publisher · View at Google Scholar
  112. R Sankaranarayanan, R Wesley, S Thara et al., “Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India,” International Journal of Cancer, vol. 106, pp. 404–408, 2003. View at Publisher · View at Google Scholar
  113. S S Shastri, K Dinshaw, G Amin et al., “Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India,” Bulletin of the World Health Organization, vol. 83, no. 3, pp. 186–194, 2005. View at Google Scholar
  114. R Sankaranarayanan, S S Shastri, P Basu et al., “The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia,” Cancer Detection and Prevention, vol. 28, no. 5, pp. 345–351, 2004. View at Publisher · View at Google Scholar · View at PubMed
  115. R Sankaranarayanan, R Rajkumar, R Theresa et al., “Initial results from a randomised trial of cervical visual screening in rural south India,” International Journal of Cancer, vol. 109, pp. 461–467, 2004. View at Publisher · View at Google Scholar
  116. R Sankaranarayanan, B M Nene, K A Dinshaw et al., “A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India,” International Journal of Cancer, vol. 116, no. 4, pp. 617–623, 2005. View at Publisher · View at Google Scholar · View at PubMed
  117. R Legood, A M Gray, C Mahé et al., “Screening for cervical cancer in India: how much will it cost? a trial based analysis of the cost per case detected,” International Journal of Cancer, vol. 117, no. 6, pp. 981–987, 2005. View at Publisher · View at Google Scholar · View at PubMed
  118. H Sriplung, S Sontipong, and N Martin, Eds., Cancer in Thailand Vol.III 1995–1997, National Cancer Institute, Bangkok, Thailand, 2003.
  119. “FIGO (International Federation of Gynecology and Obstetrics) annual report on the results of treatment in gynecological cancer,” International Journal of Obstetrics and Gynaecology, vol. 83, no. suppl 1, pp. x–xxii, 1–229, 2003.
  120. H Yoon, A Shin, S K Park, M J Jang, and M K Yoo, “Estimation of joint risks for developing uterine cervix cancer in Korea,” Korean Journal of Preventive Medicine, vol. 35, pp. 263–268, 2002. View at Google Scholar
  121. H-R Shin, D-H Lee, R Herrero et al., “Prevalence of human papillomavirus infection in women in Busan, South Korea,” International Journal of Cancer, vol. 103, no. 3, pp. 413–421, 2003. View at Publisher · View at Google Scholar · View at PubMed
  122. H-R Shin, S Franceschi, S Vaccarella et al., “Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea,” Journal of Infectious Diseases, vol. 190, no. 3, pp. 468–476, 2004. View at Publisher · View at Google Scholar
  123. K-L Liaw, A W Hsing, C-J Chen et al., “Human papillomavirus and cervical neoplasia: a case-control study in Taiwan,” International Journal of Cancer, vol. 62, no. 5, pp. 565–571, 1995. View at Publisher · View at Google Scholar
  124. H C Hsu, D Chen, C C Lin et al., “Prevalence of HPV infection in a rural county in Taiwan,” in Abstract Presented at: The 2001 Annual Meeting of Taiwan Association of Gynecology and Obstetrics, Taipei, Taiwan, May 2001.
  125. T C Jr Wright, J T Cox, L S Massad, L B Twiggs, and E J Wilkinson, “2001 consensus guidelines for the management of women with cervical cytological abnormalities,” Journal of the American Medical Association, vol. 287, no. 16, pp. 2120–2129, 2002. View at Publisher · View at Google Scholar
  126. “National Health and Medical Research Council. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen-detected abnormalities,” 2005. http://www.nhmrc.gov.au/publications/synopses/wh39syn.htm.
  127. J Melnikow, J Nuovo, A R Willan, B KS Chan, and L P Howell, “Natural history of cervical squamous intraepithelial lesions: a meta-analysis,” Obstetrics and Gynecology, vol. 92, no. 4 II suppl, pp. 727–735, 1998. View at Publisher · View at Google Scholar
  128. A-B Moscicki, “Cervical cytology testing in teens,” Current Opinion in Obstetrics and Gynecology, vol. 17, no. 5, pp. 471–475, 2005. View at Publisher · View at Google Scholar
  129. “Ontario Cervical Screening Evidence-Based Guidelines (2005) Full Report,” http://www.cancercare.on.ca/index_cervicalScreening.htm.
  130. R Klaes, A Benner, T Friedrich et al., “p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia,” American Journal of Surgical Pathology, vol. 26, no. 11, pp. 1389–1399, 2002. View at Publisher · View at Google Scholar
  131. W Chapman, C M McLachlin, D Daya et al., “P16INK4A assessment in women with CIN 1 on biopsy,” Journal of Obstetrics and Gynaecology Canada, vol. 27, p. S45, 2005. View at Google Scholar
  132. L M Elit, “Pitfalls in the diagnosis of cervical intraepithelial neoplasia 1,” Journal of Lower Genital Tract Disease, vol. 8, no. 3, pp. 181–187, 2004. View at Publisher · View at Google Scholar
  133. J MG Crane, “Pregnancy outcome after loop electrosurgical excision procedure: a systematic review,” Obstetrics and Gynecology, vol. 102, no. 5, pp. 1058–1062, 2003. View at Publisher · View at Google Scholar
  134. S-L A Samson, J R Bentley, T J Fahey, D J McKay, and G H Gill, “The effect of loop electrosurgical excision procedure on future pregnancy outcome,” Obstetrics and Gynecology, vol. 105, no. 2, pp. 325–332, 2005. View at Publisher · View at Google Scholar · View at PubMed
  135. L Sadler, A Saftlas, W Wang, M Exeter, J Whittaker, and L McCowan, “Treatment for cervical intraepithelial neoplasia and risk of preterm delivery,” Journal of the American Medical Association, vol. 291, no. 17, pp. 2100–2106, 2004. View at Publisher · View at Google Scholar
  136. P Kolstad, “Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma),” Gynecologic Oncology, vol. 33, no. 3, pp. 265–272, 1989. View at Publisher · View at Google Scholar
  137. E Burghardt, F Girardi, M Lahousen, H Pickel, and K Tamussino, “Microinvasive carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics Stage IA),” Cancer, vol. 67, no. 4, pp. 1037–1045, 1991. View at Publisher · View at Google Scholar
  138. A G Östör and R M Rome, “Micro-invasive squamous cell carcinoma of the cervix: a clinico- pathologic study of 200 cases with long-term follow-up,” International Journal of Gynecological Cancer, vol. 4, no. 4, pp. 257–264, 1994. View at Publisher · View at Google Scholar
  139. R Rome and R Brown, in Gynecologic Cancer: Controversies in Management, D Gershenson, W P McGuire, M Gore, M A Quinn, and G Thomas, Eds., pp. 133–147, Elsevier, Amsterdam, The Netherlands, 2004.
  140. W P Soutter, D Haidopoulos, R J Gornall et al., “Is conservative treatment for adenocarcinoma in situ of the cervix safe?” British Journal of Obstetrics and Gynaecology, vol. 108, no. 11, pp. 1184–1189, 2001. View at Publisher · View at Google Scholar
  141. A G Östör, “Early invasive adenocarcinoma of the uterine cervix,” International Journal of Gynecological Pathology, vol. 19, no. 1, pp. 29–38, 2000. View at Google Scholar
  142. J Balega, H Michael, J Hurteau et al., “The risk of nodal metastasis in early adenocarcinoma of the uterine cervix,” International Journal of Gynecological Cancer, vol. 14, no. 1, pp. 104–109, 2004. View at Publisher · View at Google Scholar
  143. R D Maw, M Reitano, and M Roy, “An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle,” International Journal of STD and AIDS, vol. 9, no. 10, pp. 571–578, 1998. View at Publisher · View at Google Scholar
  144. L Koutsky, “Epidemiology of genital human papillomavirus infection,” American Journal of Medicine, vol. 102, no. 5A, pp. 3–8, 1997. View at Publisher · View at Google Scholar
  145. K A Workowski and W C Levine, “Sexually transmitted diseases treatment guidelines 2002,” MMWR. Recommendations and Reports, vol. 51, no. 6, pp. 1–80, 2002. View at Google Scholar
  146. S Tatti, G Belardi, M Marini et al., “Consenso en la Metodología de Diagnóstica y Terapeutica para las Verrugas Anogenitales,” Revista Obstetricia y Ginecologia Latino-Americanas, vol. 59, no. 3, pp. 117–131, 2001. View at Google Scholar
  147. G von Krogh, C JN Lacey, G Gross, R Barrasso, and A Schneider, “European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts,” Sexually Transmitted Infections, vol. 76, no. 3, pp. 162–168, 2000. View at Publisher · View at Google Scholar
  148. “Antibiotic Writing Group. Genital (reproductive) tract infections,” in Therapeutic Guidelines: Antibiotic. Version 12, Therapeutic Guidelines, Melbourne, Australia, 2003.
  149. S K Tyring, I Arany, M A Stanley et al., “A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod,” Journal of Infectious Diseases, vol. 178, no. 2, pp. 551–555, 1998. View at Google Scholar
  150. R L Miller, J F Gerster, M L Owens, H B Slade, and M A Tomai, “Imiquimod applied topically: a novel immune response modifier and new class of drug,” International Journal of Immunopharmacology, vol. 21, no. 1, pp. 1–14, 1999. View at Publisher · View at Google Scholar
  151. H Suzuki, B Wang, G M Shivji et al., “Imiquimod, a topical immune response modifier, induces migration of Langerhans cells,” Journal of Investigative Dermatology, vol. 114, no. 1, pp. 135–141, 2000. View at Publisher · View at Google Scholar
  152. L Edwards, A Ferenczy, L Eron et al., “Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus,” Archives of Dermatology, vol. 134, no. 1, pp. 25–30, 1998. View at Publisher · View at Google Scholar
  153. D N Sauder, R B Skinner, T L Fox, and M L Owens, “Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations,” Sexually Transmitted Diseases, vol. 30, no. 2, pp. 124–128, 2003. View at Publisher · View at Google Scholar
  154. C O'Mahony, C Law, H PM Gollnick, and M Marini, “New patient-applied therapy for anogenital warts is rated favourably by patients,” International Journal of STD and AIDS, vol. 12, no. 9, pp. 565–570, 2001. View at Publisher · View at Google Scholar
  155. U B Hoyme, M Hagedorn, A-E Schindler et al., “Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment,” Infectious Diseases in Obstetrics and Gynecology, vol. 10, no. 2, pp. 79–88, 2002. View at Google Scholar
  156. D Carrasco, M vander Straten, and S K Tyring, “Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions,” Journal of the American Academy of Dermatology, vol. 47, no. 4 suppl, pp. S212–S216, 2002. View at Publisher · View at Google Scholar
  157. M Kaspari, R Gutzmer, T Kaspari, A Kapp, and J P Brodersen, “Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma,” British Journal of Dermatology, vol. 147, no. 4, pp. 757–759, 2002. View at Publisher · View at Google Scholar
  158. M F Mitchell, D Schottenfeld, G Tortolero-Luna, S B Cantor, and R Richards-Kortum, “Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis,” Obstetrics and Gynecology, vol. 91, no. 4, pp. 626–631, 1998. View at Publisher · View at Google Scholar
  159. D S Milne, V Wadehra, D Mennim, and T I Wagstaff, “A prospective follow up study of women with colposcopically unconfirmed positive cervical smears,” British Journal of Obstetrics and Gynaecology, vol. 106, no. 1, pp. 38–41, 1999. View at Google Scholar
  160. A Schneider, H Hoyer, B Lotz et al., “Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy,” International Journal of Cancer, vol. 89, no. 6, pp. 529–534, 2000. View at Publisher · View at Google Scholar
  161. M Hilgarth and M Menton, “The colposcopic screening,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 65, no. 1, pp. 65–69, 1996. View at Publisher · View at Google Scholar
  162. J M Davison and J J Marty, “Detecting premalignant cervical lesions: contribution of screening colposcopy to cytology,” Journal of Reproductive Medicine, vol. 39, no. 5, pp. 388–392, 1994. View at Google Scholar
  163. R Reid and P Scalzi, “Genital warts and cervical cancer. VII. An improved colposcopic index for differentiating benign papillomaviral infections from high-grade cervical intraepithelial neoplasia,” American Journal of Obstetrics and Gynecology, vol. 153, no. 6, pp. 611–618, 1985. View at Google Scholar
  164. C Carriero, A Di Gesu, R Conte, R Ferreri, and P Loizzi, “Grading colposcopic appearance: paired comparison between two methods for differentiating benign papillomaviral infection from high-grade dysplasia of the uterine cervix,” International Journal of Gynecology and Obstetrics, vol. 34, no. 2, pp. 139–144, 1991. View at Publisher · View at Google Scholar
  165. P D Da Forno, M R Holbrook, D Nunns, and P AV Shaw, “Long-term follow-up of patients following negative colposcopy: a new gold standard and its implications for cervical screening,” Cytopathology, vol. 14, no. 5, pp. 281–286, 2003. View at Publisher · View at Google Scholar
  166. R G Pretorius, J L Belinson, W-H Zhang, R J Burchette, P Elson, and Y-L Qiao, “The colposcopic impression. Is it influenced by the colposcopist's knowledge of the findings on the referral Papanicolaou smear?” Journal of Reproductive Medicine, vol. 46, no. 8, pp. 724–728, 2001. View at Google Scholar
  167. F X Bosch, X Castellsagué, N Muñoz et al., “Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain,” Journal of the National Cancer Institute, vol. 88, no. 15, pp. 1060–1067, 1996. View at Publisher · View at Google Scholar
  168. N Muñoz, X Castellsagué, F X Bosch et al., “Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease,” Journal of the National Cancer Institute, vol. 88, no. 15, pp. 1068–1075, 1996. View at Google Scholar
  169. X Castellsagué, F X Bosch, N Muñoz et al., “Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners,” New England Journal of Medicine, vol. 346, no. 15, pp. 1105–1112, 2002. View at Publisher · View at Google Scholar · View at PubMed
  170. C JA Hogewoning, M CG Bleeker, A JC van den Brule et al., “Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial,” International Journal of Cancer, vol. 107, no. 5, pp. 811–816, 2003. View at Publisher · View at Google Scholar
  171. World Health Organization. UNAIDS/WHO Global HIV/AIDS Online Database. http://www.who.int/globalatlas/default.asp.
  172. D J Jamieson, A Duerr, R Burk et al., “Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection,” American Journal of Obstetrics and Gynecology, vol. 186, no. 1, pp. 21–27, 2002. View at Publisher · View at Google Scholar
  173. L Ahdieh, R S Klein, R Burk et al., “Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women,” Journal of Infectious Diseases, vol. 184, no. 6, pp. 682–690, 2001. View at Publisher · View at Google Scholar · View at PubMed
  174. J M Palefsky, H Minkoff, L A Kalish et al., “Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women,” Journal of the National Cancer Institute, vol. 91, no. 3, pp. 226–236, 1999. View at Publisher · View at Google Scholar
  175. P Schuman, S E Ohmit, R S Klein et al., “Longitudinal study of cervical squamous intraepithelial lesions in human immunodefidency virus (HIV)-seropositive and at-risk HIV-seronegative women,” Journal of Infectious Diseases, vol. 188, no. 1, pp. 128–136, 2003. View at Publisher · View at Google Scholar
  176. A Duerr, B Kieke, D Warren et al., “Human papillomavirus-associated cervical cytologic abnormalities among women with or at risk of infection with human immunodeficiency virus,” American Journal of Obstetrics and Gynecology, vol. 184, no. 4, pp. 584–590, 2001. View at Publisher · View at Google Scholar · View at PubMed
  177. L S Massad, L Ahdieh, L Benning et al., “Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study,” Journal of Acquired Immune Deficiency Syndromes, vol. 27, no. 5, pp. 432–442, 2001. View at Google Scholar
  178. C Six, I Heard, C Bergeron et al., “Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women,” AIDS, vol. 12, no. 9, pp. 1047–1056, 1998. View at Publisher · View at Google Scholar
  179. T C Jr Wright, T V Ellerbrock, M A Chiasson, N Van Deventer, and X-W Sun, “Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study,” Obstetrics and Gynecology, vol. 84, no. 4 I, pp. 591–597, 1994. View at Google Scholar
  180. I Heard, J-M Tassie, V Schmitz, L Mandelbrot, M D Kazatchkine, and G Orth, “Increased risk of cervical disease among human immunodeficiency virus- infected women with severe immunosuppression and high human papillomavirus load(1),” Obstetrics and Gynecology, vol. 96, no. 2, pp. 403–409, 2000. View at Publisher · View at Google Scholar
  181. T V Ellerbrock, M A Chiasson, T J Bush et al., “Incidence of cervical squamous intraepithelial lesions in HIV-infected women,” Journal of the American Medical Association, vol. 283, no. 8, pp. 1031–1037, 2000. View at Publisher · View at Google Scholar
  182. M-C Delmas, C Larsen, B van Benthem et al., “Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. European Study Group on Natural History of HIV Infection in Women,” AIDS, vol. 14, no. 12, pp. 1775–1784, 2000. View at Publisher · View at Google Scholar
  183. H Minkoff, L Ahdieh, L S Massad et al., “The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women,” AIDS, vol. 15, no. 16, pp. 2157–2164, 2001. View at Publisher · View at Google Scholar
  184. H A Cubie, A L Seagar, G J Beattie, S Monaghan, and A RW Williams, “A longitudinal study of HPV detection and cervical pathology in HIV infected women,” Sexually Transmitted Infections, vol. 76, no. 4, pp. 257–261, 2000. View at Publisher · View at Google Scholar
  185. R D Moore and R E Chaisson, “Natural history of HIV infection in the era of combination antiretroviral therapy,” AIDS, vol. 13, no. 14, pp. 1933–1942, 1999. View at Publisher · View at Google Scholar
  186. F B Lillo, D Ferrari, F Veglia et al., “Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 184, no. 5, pp. 547–551, 2001. View at Publisher · View at Google Scholar · View at PubMed
  187. I Heard, V Potard, H Foulot, C Chapron, D Costagliola, and M D Kazatchkine, “High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women,” Journal of Acquired Immune Deficiency Syndromes, vol. 39, no. 4, pp. 412–418, 2005. View at Publisher · View at Google Scholar
  188. M Frisch, R J Biggar, E A Engels, and J J Goedert, “AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults,” Journal of the American Medical Association, vol. 285, no. 13, pp. 1736–1745, 2001. View at Publisher · View at Google Scholar
  189. D Serraino, L Dal Maso, C La Vecchia, and S Franceschi, “Invasive cervical cancer as an AIDS-defining illness in Europe,” AIDS, vol. 16, no. 5, pp. 781–786, 2002. View at Publisher · View at Google Scholar
  190. L S Massad, C T Evans, H Minkoff et al., “Natural history of grade 1 cervical intraepithelial neoplasia in women with human immunodeficiency virus,” Obstetrics and Gynecology, vol. 104, no. 5 pt 1, pp. 1077–1085, 2004. View at Publisher · View at Google Scholar · View at PubMed
  191. G M Clifford, J Polesel, M Rickenbach et al., “Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy,” Journal of the National Cancer Institute, vol. 97, no. 6, pp. 425–432, 2005. View at Publisher · View at Google Scholar · View at PubMed
  192. M Frisch, R J Biggar, and J J Goedert, “Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome,” Journal of the National Cancer Institute, vol. 92, no. 18, pp. 1500–1510, 2000. View at Publisher · View at Google Scholar
  193. J M Palefsky, E A Holly, M L Ralston et al., “Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 28, no. 5, pp. 422–428, 2001. View at Google Scholar
  194. E A Holly, M L Ralston, T M Darragh, R M Greenblatt, N Jay, and J M Palefsky, “Prevalence and risk factors for anal squamous intraepithelial lesions in women,” Journal of the National Cancer Institute, vol. 93, no. 11, pp. 843–849, 2001. View at Publisher · View at Google Scholar
  195. C A Benson, J E Kaplan, H Masur, A Pau, and K K Holmes, “Treating opportunistic infections among HIV-infected adults and adolescents—recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America,” MMWR. Recommendations and Reports, vol. 53, no. 15, pp. 1–112, 2004. View at Google Scholar
  196. S J Goldie, K A Freedberg, M C Weinstein, T C Wright, and K M Kuntz, “Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus,” American Journal of Medicine, vol. 111, no. 2, pp. 140–149, 2001. View at Publisher · View at Google Scholar
  197. S J Goldie, A D Paltiel, M C Weinstein et al., “Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection,” American Journal of Medicine, vol. 115, no. 8, pp. 632–641, 2003. View at Publisher · View at Google Scholar
  198. J S Mandelblatt, W F Lawrence, L Gaffikin et al., “Costs and benefits of different strategies to screen for cervical cancer in less-developed countries,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1469–1483, 2002. View at Google Scholar